Wire · opportunities
FDA Approves Replimune Skin Cancer Drug After Rejections
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 29 August 2026 · Fusion42 review
The FDA granted accelerated approval to Replimune's engineered viral immunotherapy, vusolimogene oderparepvec (Tudriqev), combined with nivolumab for adults with unresectable advanced cutaneous melanoma after progression on anti-PD-1 therapy. Approval was based on the single-arm IGNYTE trial showing a 24.2% objective response rate and median response duration of 14.1 months.
This Wire brief sits within Fusion42's coverage of Biotech, and 14 sources have reported it between 6 Aug 2026 and 10 Aug 2026.
◆ ◆ The Wire takeaway
The FDA's accelerated approval of Replimune opens a new pathway for immunotherapy founders targeting treatment-resistant melanoma. You need to re-examine trial designs that demonstrate clear benefit without a control arm to enter this market.
◆ Coverage
14 sources · first reported 6 Aug 2026 · latest 10 Aug 2026
◆ Topics